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modifying anti-rheumatic drugs (DMARDs) or to both
DMARDs and anti-TNFs received the RA RTX regimen (1gx2).
The clinical outcome measure was moderate/good EULAR
response at 24 weeks. Responding patients were eligible to
re-treatment with RTX upon disease exacerbation after a
minimum of 48 weeks. Costs of RTX treatment (drug acquisition
& administration) were compared to average costs of the spared
anti-TNFs (inﬂiximab, etanercept or adalimumab) that would
have been provided otherwise to each patient until RTX
re-treatment or end of follow-up (FU). Prices are based on Israeli
tariff before VAT. RESULTS: A total of 108 patients were
enrolled. Sixty-seven DMARDs failures (62%), 41 DMARDs
and anti-TNF failures (38%). At time of analysis (January 2008),
89 patients completed a minimum of 24 weeks follow-up (FU).
Three dropped out in less than 24 weeks. Median FU: 75 weeks.
35/89 patients (39%) received re-treatment with RTX at a
median of 63 weeks. A total of 37/89 patients (42%) were (at
time of analysis) still on FU with no other treatment (median FU:
93wks). Average cost in Israel of anti-TNF treatment: NIS1955
(~560$)/week Cost of RTX (2g): NIS34,448 (~$9,840). The total
saving per patient (up to data cutoff) results in NIS85,258
(~$24,360). Overall cost saving during this period for 92 patients
was NIS7,844 million (~$2,241,120). This sum is still an under-
estimation since 42% of the patients still require no further
treatment, and continue to spare anti-TNF therapy. CONCLU-
SIONS: From the payer perspective, RTX treatment is a signiﬁ-
cant cost-saving alternative for patients with RA in the Israeli
public health care setting.
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OBJECTIVES: RA is a chronic disease associated with a signiﬁ-
cant use of health care resources, imposing a substantial eco-
nomic burden to patients, health insurance and to society in
France. The objective of the present study was to assess the use of
direct medical resources excluding drug costs by RA patients in
France and to derive original costing data per level of disease
activity. METHODS: An advanced standard costing approach
was performed in collaboration with a panel of expert clinicians
highly experienced in the management of RA in France. Four
categories of disease activity were deﬁned according to DAS28
thresholds: patients (pts) achieving remission (DAS <2.6), pts not
achieving remission (DAS 2.6), pts achieving low disease activ-
ity state (LDAS; DAS 3.2) and pts not achieving LDAS (DAS
>3.2). Eight resource utilization items were deﬁned: medical
visits, laboratory tests, hospitalization, imaging, physiotherapy,
nursing, adaptive aids and transportation. Resource utilization
and unit costs from the national payer perspective were collected
and simulated using distribution ranges for each item. Using a
simulation model, a computation of all costs distributions was
performed to estimate the overall costs per six months over a
2-year time horizon. RESULTS: Direct medical costs were esti-
mated per disease activity level. For pts achieving remission
during the ﬁrst 6 months, about 90% generated costs under
€1000, with costs estimated at €771 (SD = 199) per 6 months
and €511 (SD = 162) for each subsequent 6 months (p < 0.001).
For pts not achieving remission per 6 months, about 85% gen-
erated costs under €1500, with costs estimated at €1159 per 6
months (SD = 339). For pts achieving LDAS, costs were esti-
mated at €905 (SD = 263) per 6 months and €696 (SD = 240) for
each subsequent 6 months (p < 0.001). For pts not achieving
LDAS, costs were estimated at €1215 per 6 months (SD = 405).
Key costs drivers were medical visits, laboratory tests and trans-
portation. CONCLUSIONS: This cost of illness assessment pro-
vides precise and current estimates of medical direct costs per RA
disease activity in France, conﬁrming that RA imposes a substan-
tial economic burden. The ﬁndings suggest that achieving LDAS
or remission is associated with substantially lower RA medical
costs.
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OBJECTIVES: To estimate the cost savings in outpatient
medical resource use associated with diagnosing ﬁbromyalgia
during the four years after ﬁbromyalgia diagnosis. METHODS:
A questionnaire was created based on the medical resources use
from 2260 patients diagnosed with FM between January 1998
and March 2003 in the General Practice Research Database
(FF-GPRD) in United-Kingdom. Local experts were asked to
compare their own clinical practice to UK prescriptions and
resource use, over a period of four years before diagnosis to four
plus years after diagnosis using one year cross-sections. Poisson
loglinear regression models, published for the UK, allowed to
estimate the medical resources consumed if no diagnosis had
been established. The impact of diagnosis was evaluated for each
of these medical resources. Costs were calculated by multiplying
resource use with corresponding Spanish unit costs (€; 2008;
both public health care payer perspective and societal perspec-
tive including patient co-payments). RESULTS: This study con-
ﬁrms previously published results obtained for the UK and
France: whereas costs gradually increase before diagnosis, a
stagnation in costs increase occurs in the year after diagnosis,
subsequently followed by a moderate decrease afterwards. The
savings made as a result of ﬁbromyalgia diagnosis add up to
€421 per patient and per year from the health care system per-
spective and €432 from a societal point of view. Diagnostic tests,
referrals to specialists, GP visits and drugs represent respectively
42%, 29%, 15% and 14% of these savings, CONCLUSIONS:
Compared to a diagnosed ﬁbromyalgia patient, a not diagnosed
patient in Spain represents an incremental cost of €421 from the
health care payer perspective.
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OBJECTIVES: To estimate the costs savings in outpatient
medical resource use associated with diagnosing ﬁbromyalgia
during the four years after ﬁbromyalgia diagnosis, METHODS:
A French expert panel, involving 33 general practitioners (GPs)
and 27 rheumatologists, was questioned in 2007 by means of a
questionnaire describing the UK prescriptions registered in the
General Practice Research Database between January 1998 and
March 2003 (2260 ﬁbromyalgia patients). Participating experts
were asked to describe their clinical practice compared to the UK
prescriptions in terms of diagnostic tests, drugs, consultations
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